Vital Signs clinical trials

Explore recruiting vital signs clinical trials.

Recruiting vital signs studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Vital Signs trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SPI-62 as a Treatment for Adrenocorticotropic Hormone- dependent Cushing’s Syndrome

Bulgaria, Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

Pilot Study to Evaluate Safety and Efficacy of PolyCore, a Ternary Combination of Xylitol, L-Carnitine and Polydextrin, to Treat End-Stage Kidney Disease Patients Starting Peritoneal Dialysis (EXCITE)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment regimens in transplant ineligible newly diagnosed patients.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa

Austria, Croatia, Czechia, Portugal, Slovakia, Poland +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, parallel-group, randomized, double-blind, 4-arm, placebo-controlled, multicenter study with risankizumab as active reference arm, to investigate the efficacy and safety of subcutaneous sonelokimab in male and female participants aged 18 years and over with active psoriatic arthritis and previous inadequate response or intolerance to tumor necrosis factor-α inhibitors

Spain, Czechia, Bulgaria, Poland, Hungary, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients with Suspected Vascular Disease

Italy, France, Czechia, Hungary, Spain, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Vital Signs trials by city

Vital Signs in Toronto Vital Signs in Vancouver Vital Signs in Montreal Vital Signs in Calgary Vital Signs in Edmonton Vital Signs in Ottawa Vital Signs in Winnipeg Vital Signs in Quebec City Vital Signs in Hamilton Vital Signs in Kitchener Vital Signs in London Vital Signs in Halifax Vital Signs in New York Vital Signs in Los Angeles Vital Signs in Chicago Vital Signs in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease